2.58
-0.77%
Close of 9 Nov 2026, in CHF
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Molecular Partners
Its shares trade on SIX under the ticker MOLN.SW. It has been listed since 22 October 2014. In the fiscal year to 31 December 2024, it reported revenue of CHF 5.0m and a net loss of CHF 54.0m. At that date it held total assets of CHF 158.5m and shareholders' equity of CHF 141.6m.
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich. The company went IPO on 2014-10-22. As a biopharmaceutical company, it is active in the research and development of proteins like DARPins (Designed Ankyrin Repeat Proteins), a new class of small proteins used for the development of medicine against diseases like cancer and sight-threating diseases, among others. The Company’s pipeline is structured mainly through three areas: Ophthalmology, including the creation of therapies for renital diseases like wet age-related macular degeration (wet AMD) and diabetic macular edema (DME); Oncology, containing the development of DARPins against cancer, among others; and Immunology and other Indications, entailing DARPins against several targets important for the treatment of inflammatory and auto-immune diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Oct 2014
- Employees
- 135
- Website
- molecularpartners.com ↗
Leadership
Pay as last reported
- Mr. William BurnsNon-Executive Independent Chairman of the BoardCHF 295,000
- Dr. Patrick AmstutzChief Executive Officer, Executive Director, Member of the Management Board, since 2006CHF 1.1m
- Mr. Alexander ZuercherChief Operating Officer, Member of the Management Board
- Ms. Renate GloggnerExecutive Vice President - People and Community, Member of the Management Board
- Dr. Michael StumppExecutive Vice President - Projects, Member of the Management Board
- Mr. Martin SteegmaierChief Scientific Officer
- Dr. Philippe LegenneChief Medical Officer
- Dr. Agnete FredriksenNon-Executive Independent DirectorCHF 133,000
- Dr. Dominik HoechliNon-Executive Independent DirectorCHF 135,000
- Mr. Steven HoltzmanNon-Executive Independent DirectorCHF 135,000
- Mr. Sandip KapadiaNon-Executive Independent DirectorCHF 130,000
- Dr. Vito PalombellaNon-Executive Independent DirectorCHF 125,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 74
- Environment
- 79
- Social
- 99
- Governance
- 43
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Molecular Partners AG has several key strengths that contribute to its success and competitive edge. Firstly, the company has a strong and experienced management team with deep industry expertise. This ensures effective decision-making and strategic planning. Secondly, Molecular Partners AG has a diverse and innovative product portfolio, with a focus on developing novel protein therapies. This allows the company to cater to different medical needs and target a wide range of diseases. Lastly, the company has established strong partnerships with leading pharmaceutical companies, which enables it to access additional resources, expertise, and distribution channels.
Weaknesses
- Despite its strengths, Molecular Partners AG also faces certain weaknesses that may hinder its growth and market position. One major weakness is the company's dependency on a limited number of product candidates. This increases its vulnerability to potential failures or setbacks in the development process. Additionally, the company may lack sufficient financial resources to independently fund its research and development activities, forcing it to rely heavily on partnerships and funding agreements. Moreover, Molecular Partners AG operates in a highly competitive industry, which could pose challenges in terms of market share and pricing.
Opportunities
- There are several opportunities that Molecular Partners AG can explore to drive its growth and expand its market presence. Firstly, the increasing global demand for innovative and effective therapies provides a favorable market environment for the company to introduce and commercialize its product candidates. Secondly, the growing prevalence of various diseases, such as cancer and autoimmune disorders, offers opportunities to target unmet medical needs. Molecular Partners AG can leverage its expertise in protein therapies to develop breakthrough treatments for these conditions. Additionally, expanding into new geographic markets and collaborating with emerging biopharmaceutical companies can broaden the company's customer base and diversify its revenue streams.
Threats
- Molecular Partners AG operates in an industry that is subject to various threats that may impact its business operations and profitability. Firstly, regulatory uncertainties and changing compliance requirements pose risks to the company's product development and commercialization efforts. Non-compliance or delays in obtaining necessary approvals could result in significant setbacks and increased costs. Secondly, intellectual property infringement or challenges from competitors could jeopardize Molecular Partners AG's ability to protect its proprietary technologies and product candidates. In addition, fluctuations in currency exchange rates and economic uncertainties may affect the company's financial performance, especially if it relies on international markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.